← Leaderboards
Suryaram Gummuluru
Boston University Medical Campus
$17,336,670
Attributed
$31,402,686
Total exposure
16
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,402,686 · 16
By mechanism
R01$26,964,124 · 10
UM1$2,287,003 · 1
R21$918,719 · 2
T32$839,637 · 1
R56$384,695 · 1
P41$8,508 · 1
Top collaborators
- Bjoern Markus Reinhard13 shared
- Andrew J Henderson9 shared
- Christine Cheng7 shared
- Nina H. Lin5 shared
- Gustavo Mostoslavsky5 shared
- Manish Sagar5 shared
- Shyamsunder Erramilli4 shared
- Zandrea Ambrose3 shared
Most similar at Boston University Medical Campus
Same institution · by research overlap
- Emelia J. Benjamin$25,371,486
- Douglas L Rosene$20,446,719
- Peter F Weller$19,827,145
- Jane A Leopold$4,227,925
- Vasan S. Ramachandran$64,172,892
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsVirusInfectionPreventHiv-1MediatingViralAntiretroviral TherapyMacrophageIn VivoTissuesInflammationPathogenProductionChronicInflammatory ResponseResponseInflammatoryMyeloid CellsVirionHiv InfectionsImmunePathway InteractionsPlay
Grant awards (58)
Defective HIV proviruses and Persistent Innate Immune Activation$818,391
R01 · FY2025 · AI
Mechanisms of Persistent Inflammasome Activation in Myeloid Cells$757,289
R01 · FY2025 · DA · contact PI
Persistent HIV-1 expression and microglia dysfunction$729,537
R01 · FY2025 · DA
Determinants of poor responsiveness to the booster dose of the RTS,S malaria vaccine in African children$690,500
R01 · FY2025 · AI
Improved Nanoparticle Targeting of Tissue Myeloid Cells for HIV-1 Long-acting Pre-exposure Prophylaxis$657,525
R01 · FY2025 · AI
Improved Nanoparticle Targeting of Tissue Myeloid Cells for HIV-1 Long-acting Pre-exposure Prophylaxis$788,992
R01 · FY2024 · AI
Mechanisms of Persistent Inflammasome Activation in Myeloid Cells$777,398
R01 · FY2024 · DA · contact PI
Defective HIV proviruses and Persistent Innate Immune Activation$765,274
R01 · FY2024 · AI
Persistent HIV-1 expression and microglia dysfunction$739,881
R01 · FY2024 · DA
Synergistic Mechanisms of chronic Innate Immune Activation in Microglia by Opiates and HIV Infection$664,379
R01 · FY2024 · DA · contact PI
Plasmonic Inactivation of Virus and Mycoplasma Contaminants$330,000
R01 · FY2024 · GM
Research Training in Immunology$289,176
T32 · FY2024 · AI · contact PI
Improved Nanoparticle Targeting of Tissue Myeloid Cells for HIV-1 Long-acting Pre-exposure Prophylaxis$787,467
R01 · FY2023 · AI
Persistent HIV-1 expression and microglia dysfunction$739,881
R01 · FY2023 · DA
Synergistic Mechanisms of chronic Innate Immune Activation in Microglia by Opiates and HIV Infection$677,030
R01 · FY2023 · DA · contact PI
Plasmonic Inactivation of Virus and Mycoplasma Contaminants$330,000
R01 · FY2023 · GM
Research Training in Immunology$267,103
T32 · FY2023 · AI · contact PI
Persistent HIV expression induced type I IFN responses and inflammaging$771,666
R01 · FY2022 · AG · contact PI
Persistent HIV-1 expression and microglia dysfunction$739,881
R01 · FY2022 · DA
Synergistic Mechanisms of chronic Innate Immune Activation in Microglia by Opiates and HIV Infection$689,563
R01 · FY2022 · DA · contact PI
GM3 Nanoparticles for Sustained Delivery of Anti-Retrovirals to Lymphatic Tissues$624,640
R01 · FY2022 · AI · contact PI
Plasmonic Inactivation of Virus and Mycoplasma Contaminants$330,000
R01 · FY2022 · GM
Research Training in Immunology$283,358
T32 · FY2022 · AI · contact PI
Single Cell Transcriptomics of the Opioid Use Disorder and HIV Syndemic in the Human Brain$1,105,894
UM1 · FY2021 · DA
Persistent HIV expression induced type I IFN responses and inflammaging$778,565
R01 · FY2021 · AG · contact PI
Persistent HIV-1 expression and microglia dysfunction$759,381
R01 · FY2021 · DA
Synergistic Mechanisms of chronic Innate Immune Activation in Microglia by Opiates and HIV Infection$701,970
R01 · FY2021 · DA · contact PI
GM3 Nanoparticles for Sustained Delivery of Anti-Retrovirals to Lymphatic Tissues$625,956
R01 · FY2021 · AI · contact PI
Plasmonic Inactivation of Virus and Mycoplasma Contaminants$330,000
R01 · FY2021 · GM
Single Cell Transcriptomics of the Opioid Use Disorder and HIV Syndemic in the Human Brain$1,181,109
UM1 · FY2020 · DA
Persistent HIV expression induced type I IFN responses and inflammaging$742,299
R01 · FY2020 · AG · contact PI
Synergistic Mechanisms of chronic Innate Immune Activation in Microglia by Opiates and HIV Infection$730,514
R01 · FY2020 · DA · contact PI
GM3 Nanoparticles for Sustained Delivery of Anti-Retrovirals to Lymphatic Tissues$637,477
R01 · FY2020 · AI · contact PI
Mechanism of cell-associated HIV-1 transmission$412,500
R01 · FY2020 · AI · contact PI
Persistent HIV expression induced type I IFN responses and inflammaging$737,535
R01 · FY2019 · AG · contact PI
Mechanism of cell-associated HIV-1 transmission$412,500
R01 · FY2019 · AI · contact PI
GM3 Nanoparticles for Sustained Delivery of Anti-Retrovirals to Lymphatic Tissues$401,724
R01 · FY2019 · AI · contact PI
Persistent HIV expression induced type I IFN responses and inflammaging$778,455
R01 · FY2018 · AG · contact PI
Mechanism of cell-associated HIV-1 transmission$411,771
R01 · FY2018 · AI · contact PI
GM3 Nanoparticles for Sustained Delivery of Anti-Retrovirals to Lymphatic Tissues$399,386
R01 · FY2018 · AI · contact PI
Engineering a 3D human neurovascular unit for investigating and countering neuroinflammatory mechanisms of HIV$208,500
R21 · FY2018 · NS
Mechanism of cell-associated HIV-1 transmission$411,250
R01 · FY2017 · AI · contact PI
Engineering a 3D human neurovascular unit for investigating and countering neuroinflammatory mechanisms of HIV$265,375
R21 · FY2017 · NS
Mechanism of cell-associated HIV-1 transmission$410,084
R01 · FY2016 · AI · contact PI
Mechanism of cell-associated HIV-1 transmission$405,158
R01 · FY2014 · AI · contact PI
Elucidating Non-Virus Encoded HIV Capture through Artificial Virus Nanoparticles$384,695
R56 · FY2013 · AI
Mechanism of cell-associated HIV-1 transmission$380,848
R01 · FY2013 · AI · contact PI
Mechanism of cell-associated HIV-1 transmission$405,158
R01 · FY2012 · AI · contact PI
Mechanism of cell-associated HIV-1 transmission$404,663
R01 · FY2011 · AI · contact PI
GLYCOSPHINGOLIPID COMPOSITIONS DURING INFECTION BY HIV TYPE 1 (HIV-1) PARTICLES$8,508
P41 · FY2011 · RR · contact PI
Mechanism of cell-associated HIV-1 transmission$406,250
R01 · FY2010 · AI · contact PI
Mechanism of HIV-1 attachment to dendritic cells$201,094
R21 · FY2010 · AI · contact PI
Mechanism of cell-associated HIV-1 transmission$375,554
R01 · FY2009 · AI · contact PI
Mechanism of HIV-1 attachment to dendritic cells$243,750
R21 · FY2009 · AI · contact PI
Mechanism of cell-associated HIV-1 transmission$375,554
R01 · FY2008 · AI · contact PI
Mechanism of cell-associated HIV-1 transmission$382,828
R01 · FY2007 · AI · contact PI
Mechanism of cell-associated HIV-1 transmission$394,262
R01 · FY2006 · AI · contact PI
Mechanism of cell-associated HIV-1 transmission$343,188
R01 · FY2005 · AI